937-14-4Relevant articles and documents
Method for preparing m-chloroperoxybenzoic acid by utilizing phase transfer catalysis
-
Paragraph 0026-0033, (2020/05/02)
The invention discloses a method for preparing m-chloroperoxybenzoic acid by utilizing phase transfer catalysis. The method comprises the following steps: dissolving m-chlorobenzoic acid in an organicsolvent, adding an aqueous acidic oxidant solution with a pH value of 1-4, carrying out an oxidation reaction under the action of a phase transfer catalyst, carrying out extraction separation to obtain an organic phase, drying, and separating out filter residues to obtain an organic solution containing m-chloroperoxybenzoic acid. The m-chloroperoxybenzoic acid is obtained by catalyzing the reaction of m-chlorobenzoic acid and an oxidant through the phase transfer catalyst, the raw materials are stable in properties, cheap and easy to obtain, the process is simple and easy to control, the solvent can be recycled, the product yield is high, the yield of the m-chloroperoxybenzoic acid can reach 82% or above, and large-scale industrial production is facilitated.
One-pot method for preparing diepoxide (by machine translation)
-
Page/Page column 6-9, (2020/05/01)
The method comprises the following steps, adding a reducing agent water solution :S1. to a reactor: slowly dropwise adding a reducing agent aqueous solution to obtain the diepoxide, adding a reducing agent aqueous solution to the reactor, to obtain the diepoxy, and separating and purifying ;S2. from the organic phase: by one-pot reaction, and adding a reducing agent water, through a pot method to obtain the diepoxide crude solution, to obtain the diepoxide compound. The invention discloses a method for separating and purifying a diepoxide crude product through a high vacuum, distillation . The method comprises the following steps of: adding a reducing agent aqueous solution to the, reactor at a low temperature, to obtain a diepoxide 91% crude, product through 95% a, one-pot reaction, of the diolefin and the m-chloroperoxybenzoic acid solution to obtain a diepoxide crude product solution. (by machine translation)
Synthetic method for drug intermediate m-chloroperbenzoic acid
-
Paragraph 0016-0019; 0020-0023; 0024-0027, (2018/07/30)
The invention discloses a synthetic method for the drug intermediate m-chloroperbenzoic acid. The synthetic method comprises the following steps: adding m-chlorophenylacetamide and a sodium nitrate solution into a reaction vessel, controlling a stirring speed to be 230-260 rpm and a solution temperature to be 10-16 DEG C, adding a methyl n-butyl ether solution and a 1,4-butanediol solution, addingN-bromoacetamide in batches within 20-40 min, and continuing a reaction for 60-90 min; and then adding an aqueous solution and zinc fluoride powder, controlling a stirring speed to be 310-330 rpm, continue the reaction for 3-4 h, carrying out washing with a sodium chloride solution for 30-50 min, then carrying out washing with a 3-heptanol solution for 20-40 min, carrying out recrystallization ina nitroethane solution, and then carrying out dehydration with a dehydrating agent so as to obtain the finished m-chloroperoxybenzoic acid.
Copper Tetrasulfophthalocyanine Intercalated Hydrotalcite as an Efficient Bifunctional Catalyst for the Baeyer–Villiger Oxidation
Zhou, Weiyou,Chen, Yong,Qian, Junfeng,Sun, Fu’an,He, Mingyang,Chen, Qun
, p. 2157 - 2164 (2016/10/18)
Abstract: A heterogeneous bifunctional hybrid catalyst originated from copper tetrasulfophthalocyanine (CuPcTs) and hydrotalcite for Baeyer–Villiger (B-V) oxidation has been prepared and characterized. XRD, FTIR, DR UV-Vis and SEM characterization indicate that CuPcTs molecule has been successfully intercalated into the layer of ZnAl hydrotalcite. And the synthesized hybrid exhibited excellent catalytic activity in the B-V oxidation for various ketones under mild conditions. Its bifunctional role in the reaction through O2/benzaldehyde has been discussed and verified by controlled experiments. The study indicates that the designed catalyst not only catalyzes the oxidation of benzaldehyde to perbenzoic acid, but also accelerates the transformation of ketone to lactone or ester. Graphical Abstract: [Figure not available: see fulltext.]
METHOD FOR PRODUCING AMIDE COMPOUND
-
Page/Page column 25; 27, (2010/01/29)
Disclosed is a method for producing an amide compound represented by the formula (3) below and having an excellent control activity against a harmful arthropod, which is characterized in that an aniline compound represented by the formula (1) below and an aldehyde compound represented by the formula (2) below are reacted in a solvent in the presence of an oxidizing agent such as oxygen or a peroxide. (In the formulae below, R1, R2 and R3 independently represent a C1-C6 alkyl group which may be substituted by a halogen atom, or the like; and R4, R5, R6 and R7 independently represent a halogen atom or the like.)
TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS
-
, (2008/06/13)
Compounds of formula (I), wherein: X is hydrogen, halogen, CF3, nitro, NH2 or lower alkyl; each X is independently selected from the group consisting of hydrogen, halogen, lower alkoxy and lower alkyl; n is 1 or 2; Y is selected from the group consisting of S(O)p, O, and NR, wherein p is 0, 1 or 2, and R is hydrogen, alkyl, aryl, cycloalkyl, loweralkoxycarbonyl, aminocarbonyl or acyl; R and R, which may be the same or different, are selected from the group consisting of hydrogen and lower alkyl groups, or taken together can form an oxygen atom when Y is NR; A..... is C=, CH- or N-; R is -CZ-Y-Y-R, wherein: Z is O, =CH-CN, or =N-CN; one of Y and Y is a bond, -CO-, O, S, or -NR-, and the other is (CH2)m, where m is 0 or an integer of 1 to 4, and R is H or alkyl, with the previso that when Z is O and m is 0 then Y or Y is selected form -CO-, O, S, or -NR; R is aryl, heteroaryl or heterocycloalkyl, with proviso that R can also be lower alkyl when Z is =N-CN; and their pharmaceutically acceptable acid additions salts; have activity as Ras-FPT inhibitors. They can be used, e.g., in pharmaceutical compositions, for inhibiting the abnormal growth of cells and for inhibiting proliferative diseases. Processes for their preparation, and useful intermediates, are also disclosed.
Pyrazinone thrombin inhibitors
-
, (2008/06/13)
Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein A is
Tricyclic compounds having activity as RAS-FPT inhibitors
-
, (2008/06/13)
Compounds of Formula I: wherein: X1 is hydrogen, halogen, CF3, nitro, NH2 or lower alkyl; each X2 is independently selected from the group consisting of hydrogen, halogen, lower alkoxy and lower alkyl; n is 1 or 2; Y is selected from the group consisting of S(O)p, O, and NR5, wherein p is 0, 1 or 2, and R5 is hydrogen, alkyl, aryl, cycloalkyl, loweralkoxycarbonyl, aminocarbonyl or acyl; R1 and R2, which may be the same or different, are selected from the group consisting of hydrogen and lower alkyl groups, or taken together can form an oxygen atom when Y is NR5; A . . . is C=, CH- or N-; R is -CZ-Y1-Y2-R3, wherein: Z is O, =CH-CN, or =N-CN; one of Y1 and Y2 is a bond, -CO-, O, S, or -NR4-, and the other is (CH2)m, where m is 0 or an integer of 1 to 4, and R4 is H or alkyl, with the proviso that when Z is O and m is 0 then Y1 or Y2 is selected from -CO-, O, S, or -NR4; R3 is aryl, heteroaryl or heterocycloalkyl, with the proviso that R3 can also be lower alkyl when Z is =N-CN; and their pharmaceutically acceptable acid addition salts; have activity as Ras-FPT inhibitors. They can be used, e.g., in pharmaceutical compositions, for inhibiting the abnormal growth of cells and for inhibiting proliferative diseases. Processes for their preparation, and useful intermediates, are also disclosed.
Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia
-
, (2008/06/13)
The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
Pyrimidine derivatives and guanine derivatives, and their use in treating tumor cells
-
, (2008/06/13)
The present invention provides certain 6-hetarylalkyloxy pyrimidine derivatives of formula II wherein R is (i) a cyclic group having at least one 5- or 6-membered heterocyclic ring, optionally with a carbocyclic or heterocyclic ring fused thereto, the or each heterocyclic ring having at least one hetero atom chosen from O, N, or S, or a substituted derivative thereof; or (ii) phenyl or a substituted derivative thereof, R2 is selected from H, C1-C5 alkyl, halogen or NH2, R4 and R5 which are the same or different are selected from H, NH2 or NOn where n=1 or 2, or R4 and R5 together with the pyrimidine ring form a 5- or 6-membered ring structure containing one or more heterocyclic atoms, and pharmaceutically acceptable salts thereof, exhibit the ability to deplete O6-alkylguanine-DNA alkyltransferase (ATase) activity.
